Benefits for Low Birth Weight Infants

One hundred and sixty-two low birth weight infants, weighing less than 1,500 g, were divided into two groups: one group was administered B. breve M-16V and the other (control) was not. As a result, the incidence of infectious diseases was inhibited by B. breve M-16V administration. Furthermore, the body weight on the expected date of delivery was increased by B. breve M-16V administration, resulting in a shorter duration of hospitalization.

Effects of B. breve M-16V administration for preventing infection and promoting the growth of low birth weight infants Percentage of low birth weight infants having bifidobacteria in the faces during B. breve M-16V administration

B. breve M-16V was administered to low birth weight infants weighing 1,000 to 2,000 g. In the group not administered B. breve M-16V (control), the rates of detection of bifidobacteria were low during the test period. In contrast, in the group administered B. breve M-16V, bifidobacteria were detected in significant numbers of infants at week 1, and then the detection rates became 100% at and after two weeks of administration.

This information is not intended for the final consumer. This is based on the research and our development work and is, to the best of our knowledge, reliable. However, Morinaga does not assume any liability or risk involved in the use of its final products, and Manufactures should check regulatory status of any claims according to the intended use of their products.